Legend Holdings-backed Berry Genomics will list through a reverse merger with auto parts maker Chengdu Tianxing Instrument & Meter in a deal that values it at $619m.
Berry Genomics, a China-based genetic testing service provider backed by conglomerate Legend Holdings, is set to go public through a reverse merger with auto parts producer Chengdu Tianxing Instrument & Meter, China Money Network reported yesterday.
Shenzhen-listed Tianxing will acquire Berry in an all-share deal that will involve it issuing $619m worth of new shares.
Founded by former employees of DNA testing company Beijing Genomics Institute in 2010, Berry offers a range of genetic screening services including prenatal DNA screening,…
